Brief: Canbridge Pharmaceuticals Says Granted Marketing Approval By NMPA For Livmarli
02/06/2023 02:14
June 2 (Reuters) - Canbridge Pharmaceuticals Inc
1228.HK :
* GRANTED MARKETING APPROVAL BY NMPA OF CHINA
* APPROVAL CO'S LIVMARLI
Further company coverage: 1228.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CANbridge Pharmaceuticals
See all newsChina's CANbridge Pharmaceuticals H1 revenue rises on Hunterase and Livmarli strength
Brief: CANbridge Pharmaceuticals Posts HY Loss of RMB37.1 MLN
Brief: Canbridge Pharmaceuticals Says Livmarli Obtains NHIA Reimbursement Approval In Taiwan For ALGS And PFIC
Brief: Canbridge Pharmaceuticals Initiates Registration And Launch Preparations For Gaurunning In North African Market
CANbridge Pharmaceuticals jumps as WuXi Biologics buys shares